DNA methylation-based analysis of leukocyte landscape in children with atopic dermatitis
- PMID: 40056216
- DOI: 10.1007/s00403-025-04018-z
DNA methylation-based analysis of leukocyte landscape in children with atopic dermatitis
Abstract
Atopic dermatitis (AD) is the most common chronic, inflammatory skin condition among the pediatric population. There is a need to better characterize the leukocytic landscape of AD for disease stratification, surveillance, and to identify therapeutic targets. We utilized a novel DNA methylation (DNAm)-based algorithm to study a publicly available, epigenome-wide DNAm dataset of pediatric AD patients and healthy subjects. In this pediatric cohort, AD was associated with significantly lower estimated proportions of memory B, memory CD4 T, naïve CD4 T, naïve CD8 T, and NK cells, but higher proportions of eosinophils and Tregs. Patients with lower IgE (< 500 IU/mL) had lower abundance of naïve B cells and higher abundance of eosinophils. Males had higher eosinophil abundance than female patients. This study corroborates existing on data on leukocytic populations in AD and demonstrates a scalable method for leukocyte quantification, that may be expanded to allow for better correlation to clinical presentation.
Keywords: Atopic dermatitis; DNA-methylation; Epigenetics; Leukocytes.
© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Patient consent: Not applicable. IRB approval status: Not applicable. Clinical trials registration number: Not applicable. Competing interests: Dr. Vincent Piguet has received honoraria or fees for consulting and/or speaking for AbbVie, Almirall, Celgene, Janssen, Novartis, and Pfizer and has received departmental support for Cardiff University from AbbVie, Almirall, Alliance, Beiersdorf UK Ltd, Biotest, Celgene, Dermal, Eli Lilly, Galderma, Genus Pharma, Globe Micro, Janssen‐Celag, La Roche‐Posay, L’Oreal, LEO Pharma, Meda, MSD, Novartis, Pfizer, Sinclair Pharma, Spirit, Stiefel, Samumed, Thornton Ross, TyPham, and UCB and for University of Toronto from Sanofi.
References
-
- Brunner PM, Guttman-Yassky E, Leung DYM (2017) The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol 139:S65–S76. https://doi.org/10.1016/j.jaci.2017.01.011 - DOI - PubMed - PMC
-
- Salas LA, Zhang Z, Koestler DC et al (2022) Enhanced cell Deconvolution of peripheral blood using DNA methylation for high-resolution immune profiling. Nat Commun 13:761. https://doi.org/10.1038/s41467-021-27864-7 - DOI - PubMed - PMC
-
- Chen K, Kuo H (2020) Genomic CpG methylation profiles of peripheral blood mononuclear cells in childhood AD patients and control subjects. Gene Expression Omnibus, p GSE152084
-
- Čelakovská J, Čermáková E, Boudkova P, Krejsek J (2024) The changes of leukocytes and T lymphocytes in atopic dermatitis patients with and without dupilumab therapy and in control group in pollen season compared to out of pollen season. J Dermatological Treat 35:2318351. https://doi.org/10.1080/09546634.2024.2318351 - DOI
-
- Czarnowicki T, He H, Canter T et al (2020) Evolution of pathologic T-cell subsets in atopic dermatitis from infancy to adulthood. J Allergy Clin Immunol 145:215–228. https://doi.org/10.1016/j.jaci.2019.09.031 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
